Bibliographic detailsThompson MF, Chen L, Tangirala M, Asmar L, Jones SE. Cost-effectiveness of docetaxel-cyclophosphamide versus doxorubicin-cyclophosphamide for breast cancer. American Journal of Pharmacy Benefits 2011; 3(5): 276-283
StatusThis is an economic evaluation that meets the criteria for inclusion on NHS EED.
Indexing statusSubject indexing assigned by CRD
Index termsBreast Neoplasms; Cyclophosphamide; Doxorubicin; Humans; Taxoids